ABT vs SNSE · P/E 25, rev $44.33B vs $18.6M cap
Abbott Laboratories (ABT) versus Sensei Biotherapeutics Inc (SNSE) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Sensei Biotherapeutics Inc (SNSE) is a biotechnology company listed on NASDAQ.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
SNSE does not have a complete income-statement cache yet.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. SNSE currently screens at market cap $18.6M.
Not investment advice. Open the ABT and SNSE stock pages for the full models.
Not investment advice.